Application of revafenib in preparation of medicine for treating melanoma

By using revafenib in melanoma treatment, the growth and metastasis of melanoma cells is inhibited, and the effectiveness of existing treatment methods is solved, effective inhibition and apoptosis induction of melanoma cells is achieved, and the A new therapeutic strategy.

CN119015279APending Publication Date: 2024-11-26TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411309563.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The effectiveness of existing melanoma treatment methods is limited by postoperative recurrence, hyposensitivity, toxic side effects and drug resistance, and the application of rivafenib in melanoma is limited, and its anti-melanoma mechanism has not been clarified.

Method used

Revafenib is used to prepare drugs for the treatment of melanoma. By inhibiting the growth, invasion and metastasis of melanoma cells, it promotes apoptosis of cancer cells and reduces the expression of RRM2 and ERK/E2F3 signals as a new therapeutic strategy.

Benefits of technology

Revafenib significantly inhibits the proliferation, invasion and metastasis of melanoma cells, induces apoptosis, and reduces RRM2 expression, providing a new melanoma treatment method, which is safe and effective.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015279A_ABST
    Figure CN119015279A_ABST
Patent Text Reader

Abstract

The invention discloses an application of revapanib in treatment of melanoma, and provides a new application of revapanib and a medicine for treating melanoma, and research results show that revapanib promotes apoptosis of cancer cells by inhibiting proliferation, invasion and metastasis of melanoma cells so as to induce death of the melanoma cells, so that the application of revapanib in treatment of melanoma is realized, and the application of revapanib in treatment of melanoma is realized. The revapanib reduces the expression of RRM2 in melanoma cells and the activation of an ERK / E2F3 signal channel.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to the use of revavafenib in preparing a drug for treating melanoma. Background Art

[0002] Melanoma is a malignant tumor that develops from melanocytes, and its incidence continues to rise worldwide. Surgery, chemotherapy, biological therapy, skin-directed therapy, and radiotherapy are widely used to treat melanoma. However, the effectiveness of these therapies is limited by postoperative recurrence, low sensitivity, toxic side effects, and drug resistance. Therefore, new alternative therapies are urgently needed for melanoma.

[0003] Melanoma is prone to metastasis at an early stage, so the prognosis is relatively poor. Metastasis is a complex process that requires a high degree of angiogenesis. Therefore, inhibiting angiogenesis may become a promising treatment method. It is well known that vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) are essential for the angiogenesis process. It is worth noting that revavafenib is a small molecule inhibitor of multiple protein kinases (including VEGFR1 / 2 / 3 and PDGFR-β), which is reported to inhibit tumor angiogenesis and growth as well as matrix formation. However, the exact mechanism by which revavafenib inhibits the onset of cancer has not been fully elucidated. Several clinical studies have shown that revavafenib appears to have a wide range of anticancer effects on various solid tumors. For example, in colorectal cancer and advanced gastrointestinal stromal tumors (GIST), revavafenib can improve the overall survival and progression-free survival of cancer patients. However, research on the use of revavafenib in melanoma patients is still limited. In the prior art, revavafenib is often used to treat metastatic colorectal cancer, and it is unclear whether it has an anti-tumor effect in melanoma, and its anti-melanoma mechanism has not been studied. Summary of the invention

[0004] The main purpose of the present invention is to propose the use of revavafenib in the preparation of drugs for treating melanoma, aiming to provide a new application of revavafenib for the preparation of drugs for treating melanoma.

[0005] To achieve the above objectives, the present invention proposes the use of rivafenib in the preparation of a drug for treating melanoma.

[0006] Preferably, the revavafenib is capable of limiting the growth, invasion and metastasis of melanoma cells.

[0007] Preferably, revavafenib upregulates apoptosis-inducing markers, including activated PARP and Bax.

[0008] Preferably, rivafenib exerts its effect against melanoma progression by reducing RRM2 expression.

[0009] Ribonucleotide reductase (RR) consists of two subunits named RRM1 and RRM2 and is required for DNA repair and replication. The expression of RRM1 protein is basically stable throughout the life cycle of the cell, but the expression of RRM2 protein fluctuates dynamically as the cell is stimulated. Studies have shown that RRM2 is involved in the regulation and modification of proteins. In addition, RRM2 plays a vital role in the etiology of cancer and is a regulator of certain oncogenes. In addition, RRM2 is also a potential biomarker for many cancers, such as bladder cancer and lung adenocarcinoma. Targeting RRM2 in melanoma is a new strategy.

[0010] Preferably, RRM2 is the target of rivafenib in melanoma.

[0011] RRM2 is expressed at elevated levels in most malignancies and is considered an oncoprotein. Related studies have shown that RRM2 is a target of ubiquitin-specific processing protease (USP) 7 and is regulated by USP7 during the S phase of the cell cycle. Genetic and pharmacological inhibition of USP7 can induce senescence in melanoma cells. Combination therapy with the bifunctional histone deacetylase (HDAC) / LSD1 inhibitor domatinostat and the USP7 inhibitor P5091 can benefit melanoma patients. In addition, RRM2 is considered a new target of sorafenib and partially contributes to the anticancer activity of sorafenib in liver cancer cells. Similarly, our results suggest that RRM2, as a target of rivafenib, is involved in the inhibitory effect of rivafenib on melanoma growth.

[0012] Preferably, revavafenib inhibits the pathogenesis of melanoma via the ERK / E2F3 / RRM2 axis.

[0013] Preferably, the drug further comprises pharmaceutically acceptable excipients.

[0014] Preferably, the drug is an oral preparation or an injectable preparation.

[0015] Compared with the prior art, the beneficial effects of the present invention are:

[0016] The present invention provides a new use of revavafenib for preparing a drug for treating melanoma. The research results of the present invention show that revavafenib induces melanoma cell death by inhibiting the proliferation, invasion and metastasis of melanoma cells and promoting apoptosis of cancer cells. Revavafenib reduces the expression of RRM2 and ERK / E2F3 signals in melanoma cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0018] Figure 1 This is a graph showing that revavafenib in Example 3 of the present invention can significantly inhibit the growth of melanoma cells. Figure 1 A shows that rivafenib has significant cytotoxicity to melanoma cells in a concentration- and time-dependent manner; Figure 1 BG: Revavafenib significantly inhibited the growth of melanoma cells by cell colony formation (BD) and EdU staining (EG, scale bar: 100 μm); Figure 1 H shows that dose-dependent revavafenib treatment blocked the transition from G1 to S in the cell cycle of the Sk-Mel-2 / 28 cell line; Figure 1 I shows that revavafenib reduced the levels of CDK4 and cyclin D1 (G1 phase regulatory protein) in the Sk-Mel-2 / 28 cell line; Reg: revavafenib, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, data are expressed as mean + / - SEM, and similar results were obtained in two other independent experiments, and data are expressed as mean + / - SEM;

[0019] Figure 2 This is a graph showing that revavafenib in Example 3 of the present invention has no cytotoxicity to normal human skin cells (including HEM and Hacat cells); Reg: revavafenib, *P<0.05, **P<0.01, ***P<0.001, ns: no significance, data are expressed as mean + / - SEM;

[0020] Figure 3 This is a graph showing the ability of revavafenib in Example 3 of the present invention to inhibit the invasion and migration of melanoma cells; Figure 3 A shows that rivafenib reduces the proportion of invasive cells; Figure 3 BD shows that revavafenib significantly reduced the number of migrating cells and inhibited the migration of melanoma cells, Reg: revavafenib, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, data are expressed as mean + / - SEM, and similar results were obtained in two other independent experiments, (A+B) scale bar: 100μm. (C+D) scale bar: 200μm;

[0021] Figure 4This is a diagram showing rivafenib inducing apoptosis of melanoma cells in Example 3 of the present invention; Figure 4 AB showed that after melanoma cells were treated with Regorafenib for 48 h, the expression of Bax and activated PARP increased, while the expression of Bcl-2 decreased, which was confirmed by Western blot analysis (A) and immunofluorescence staining (B, scale bar: 50 μm); Figure 4 C shows that by FCM, revavafenib increased the proportion of apoptotic cells, Reg: revavafenib, **p<0.01, ****p<0.0001, data are expressed as mean + / - SEM, and similar results were obtained in two other independent experiments;

[0022] Figure 5 The figure shows that RRM2 in Example 3 of the present invention is a downstream target of rivafenib; Figure 5 PCA in AB showed significant differences between rivafenib-treated and control samples; Figure 5 C 1502 upregulated and 780 downregulated differentially expressed genes (DEGs) were found in rivafenib-treated samples by RNA-seq; Figure 5 The downregulated DEGs were used for enrichment analysis; Figure 5 F Combining the analysis of RNA-seq_down genes and GSE7553_up genes, 25 overlapping differentially expressed genes (ODEGs) were identified; Figure 5 G When melanoma cells were treated with different concentrations of rivafenib, the level of RRM2 protein was suppressed; Figure 5 H Binding mode of regvafenib and RRM2 predicted by docking analysis, Reg: regvafenib, **p<0.01, ***p<0.001, ****p<0.0001, data are expressed as mean + / - SEM, and similar results were obtained in two other independent experiments;

[0023] Figure 6 This is a graph showing the mRNA level detection of the gene in Example 3 of the present invention; Figure 6 The mRNA changes of GINS2, RRM2, FEN1 and UHRF1 are shown in the figure; Reg: rivafenib. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns: no significance, data are expressed as mean + / - SEM;

[0024] Figure 7 This is a diagram showing that silencing RRM2 can alleviate the malignant behavior of melanoma cells in Example 3 of the present invention; Figure 7 A The silencing efficiency of RRM2 was confirmed by Western blot analysis; Figure 7BE, by CCK8 (B) and EDU staining (CE), the loss of RRM2 significantly inhibited the proliferation of Sk-Mel-2 / 28 cells; Figure 7 FI silencing of RRM2 reduced the number of invasive melanoma cells (FH) and inhibited the migration of melanoma cells (I), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, data are expressed as mean + / - SEM, and similar results were obtained in two other independent experiments, (C+F) Scale bar: 100 μm;

[0025] Figure 8 This is a transfection efficiency diagram of the RRM2 overexpression plasmid in Example 3 of the present invention; the data are expressed as mean + / - SEM, and similar results were obtained in two other independent experiments;

[0026] Fig. 9 This is a graph showing that overexpression of RRM2 in Example 3 of the present invention partially reversed the melanoma cell growth inhibition induced by revavafenib; Fig. 9 A Overexpression of RRM2 partially reversed revavafenib-induced cytotoxicity in melanoma cells as measured by CCK8 cytotoxicity assay. Fig. 9 BC detected by FCM, RRM2 overexpression partially alleviated revavafenib-induced apoptosis in melanoma cells; Fig. 9 DE Through transell experiment, RRM2 overexpression can partially reverse the inhibition of revavafenib on melanoma cell invasion and migration; Scale bar: 100 μm, Reg: revavafenib, ***p<0.001, ****p<0.0001, data are expressed as mean + / - SEM, and similar results were obtained in two other independent experiments;

[0027] Fig.10 This is a diagram showing that the ERK / E2F3 signal is involved in the inhibitory effect of rivafenib on melanoma cells in Example 3 of the present invention; Fig.10 A is the expression of phosphorylated ERK (p-ERK) and E2F3 detected by immunoblotting in melanoma cells after treatment with revavafenib; Fig.10 B shows that when ERK signaling was blocked, the levels of p-ERK, E2F3, and RRM2 decreased; Fig.10 C shows that when E2F3 expression is reduced, RRM2 expression is also reduced; Reg: rivafenib, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Data are expressed as mean + / - SEM, and similar results were obtained in two other independent experiments;

[0028] Fig.11 This is a diagram of a tumor xenograft experiment in Example 3 of the present invention; Fig.11 A is the in vivo test flow chart; Fig.11 BD showed that revavafenib inhibited the growth of xenograft tumors, including tumor weight ( Fig.11 C) and volume ( Fig.11 D). Fig.11 E shows that there were no obvious tissue changes in important organs of the control group and the rivafenib treatment group; scale bar: 50 μm, Reg: rivafenib, ***P<0.001, data are expressed as mean + / - SEM;

[0029] Fig.12 This is a diagram showing that revavafenib in Example 3 of the present invention inhibits the growth of melanoma in vivo; Fig.12 AC showed that revavafenib inhibited the growth of xenograft tumors, including tumor weight (B) and volume (C); Fig.12 D shows that rivafenib treatment suppressed the levels of p-ERK and RRM2, while overexpression of RRM2 partially alleviated the suppression of p-ERK and RRM2 expression; Fig.12 E shows that there were no significant differences in the weights of these important organs between the control group and the rivafenib-treated group; **p<0.01, ***p<0.001, ****p<0.0001, data are expressed as mean + / - SEM, and similar results were obtained in two other independent experiments.

[0030] The realization of the purpose, functional features and advantages of the present invention will be further explained in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION

[0031] To make the purpose, technical scheme and advantages of the embodiment of the present invention clearer, the technical scheme in the embodiment of the present invention will be clearly and completely described below. If the specific conditions are not specified in the embodiment, it is carried out according to the normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified in the reagents or instruments used, they are all conventional products that can be purchased commercially. In addition, the technical schemes between the various embodiments can be combined with each other, but must be based on the ability of ordinary technicians in the field to achieve. When the combination of technical solutions is contradictory or cannot be achieved, it should be considered that the combination of such technical solutions does not exist, and is not within the scope of protection required by the present invention. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without making creative work belong to the scope of protection of the present invention.

[0032] The technical solution of the present invention is further described in detail below in conjunction with specific embodiments and drawings. It should be understood that the following embodiments are only used to explain the present invention and are not used to limit the present invention.

[0033] It should be noted that, unless otherwise specified, all reagents or instruments used without indicating the manufacturer are conventional products that can be purchased commercially.

[0034]

[0035]

[0036] Example 1 Cell culture

[0037] Human melanoma cells (A2058, SK-MEL-2, SK-MEL-28, and MUM-2B) were purchased from Shanghai Jinyuan Biotechnology Co., Ltd. (Shanghai, China). A2058 was grown in DMEM medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, #10270-106, Gibco, USA); SK-MEL-2, SK-MEL-28, and MUM-2B were grown in RPMI-1640 medium (Gibco, USA) supplemented with 10% FBS. Normal human skin cells (HEM and Hacat) were provided by ATCC Cell Bank and PriCells (Wuhan, China), respectively. HEM was cultured in RPMI-1640 medium (Gibco, USA) supplemented with 10% FBS; Hacat was cultured in DMEM medium (Gibco, USA) supplemented with 10% FBS.

[0038] Example 2 Drug Preparation

[0039] Revafenib (#755037-03-7, ApexBio, USA) was dissolved in dimethyl sulfoxide (DMSO) with a stock concentration of 10 mM and stored at -20°C. In the in vitro study, different concentrations (0, 2.5, 5, 10 μM) of Revafenib were used in different experiments.

[0040] Example 3 Experimental test and result analysis

[0041] (1) CCK8 cytotoxicity assay

[0042] The cytotoxic effect of revavafenib on melanoma cells (A2058, SK-Mel-2, SK-Mel-28 and MUM-2B) and normal human skin cells was evaluated by CCK8 assay. Cells (5000 cells / well) were seeded into 96-well plates and treated with revavafenib at different concentrations (0, 2.5, 5, 10 μM) starting 12 hours later. Cells were cultured in the presence of revavafenib for 24 hours or 48 hours. At the end of each culture period, 10 μl of CCK-8 solution (ApexBio, USA) was added to each well. After 1.5 hours of culture, the absorbance at a wavelength of 450 nm was detected. Three independent tests were repeated.

[0043] CCK8 cytotoxicity assay showed that rivafenib had a dose-dependent cytotoxic effect on melanoma cells ( Figure 1 A). However, rivafenib was not cytotoxic to normal human skin cells, including HEM and Hacat cells ( Figure 2 ). These results confirm the safety of rivafenib at effective doses.

[0044] (2) EdU test

[0045] EdU detection was performed using BeyoClick TM EdU-594 detection kit (C0078S, Beyotime, China) was used according to the manufacturer’s protocol. We observed that 2.5, 5, and 10 μM revavafenib significantly inhibited melanoma cell proliferation after 48 h of treatment. Therefore, we used the 48 h time point of revavafenib treatment for further experiments. Meanwhile, 10 μM revavafenib was slightly less toxic to Sk-Mel-2 and Sk-Mel-28 cell lines compared with A2058 and MUM-2B, so we chose Sk-Mel-2 and Sk-Mel-28 cell lines for further experiments. 1000 SK-MEL-2 / 28 cells were seeded into 6-well plates and incubated with revavafenib (0, 2.5, 5, 10 μM) for 48 h. After incubation with 10 μM EdU for 2 h, the cells were fixed with 4% paraformaldehyde for 15 min and permeabilized with tritonX-100 for 20 min. Then, the incorporated EdU was visualized by click reaction for 30 min, and nuclear DNA was stained for 30 min with Hoechst 33342. Finally, proliferating cells were observed using fluorescence microscopy, and the percentage of EdU-positive cells was assessed using ImageJ software. Three independent assays were repeated.

[0046] The results showed that revavafenib significantly reduced the proportion of EdU-positive proliferating cells, indicating that revavafenib can delay the proliferation of melanoma cells ( Figure 1 EG).

[0047] (3) Cell colony formation assay

[0048] 100 SK-MEL-2 and SK-MEL-28 cells were seeded into 6-well plates. Cells were treated with 0, 2.5, 5, and 10 μM concentrations of rivafenib, and the medium was changed every 3 days. Colony formation ended after 2 weeks of culture or when the number of cells in most individual clones exceeded 50. The colonies were fixed with 4% paraformaldehyde and stained with crystal violet for 15 minutes. The colonies were photographed using a microscope and a digital camera, and the number of colonies was counted by Image J software. Three independent tests were repeated.

[0049] The results showed that revavafenib significantly reduced the number of cell colonies, indicating that revavafenib can delay the proliferation of melanoma cells ( Figure 1 BD).

[0050] (4) Flow cytometry (FCM)

[0051] To further explore the mechanism of melanoma cell proliferation inhibition induced by revavafenib, we used FCM to detect the cell cycle distribution of Sk-Mel-2 and Sk-Mel-28 cells after treatment with revavafenib at 0, 2.5, 5, and 10 μM concentrations. Cell apoptosis and cell cycle analysis were performed using a revavafenib-treated cell apoptosis detection kit (AP104, Lianke Bio, China) and a cell cycle analysis kit (40301ES60, Yisheng Bio, China). Briefly, 5×10 4 Melanoma cells were treated with 0, 2.5, 5, and 10 μM revaccib for 48 hours. The cells were then collected and counted, fixed or not fixed with 4% paraformaldehyde, and the staining solution was prepared (the staining solution for AP104 was 5× binding buffer, the staining solution for 40301ES60 was [40301-C], the dyes for AP104 were AnnexinV-PE and 7-AAD, and the dye for 40301ES60 was PI), and then the cells were placed in the staining solution and incubated in the dark at 37°C for 5 or 30 minutes. The staining solution was then removed and the stained cells were detected by FCM. The frequency and cell cycle distribution of apoptotic cells were analyzed using FlowJo software. Three independent tests were repeated.

[0052] The results showed that rivafenib treatment blocked the G1-to-S transition of the cell cycle in both melanoma cell lines in a dose-dependent manner. Figure 1 H), which prevented the growth of melanoma cells.

[0053] (5) Western blot analysis

[0054] SK-MEL-2 and SK-MEL-28 cells were treated with 0, 2.5, 5, and 10 μM revaccine for 48 h. Total cellular protein was extracted on ice with RIPA buffer (Solerbo, China) supplemented with 1% phosphatase inhibitors and then quantified using a BCA protein assay kit (Biyuntian, China). Protein samples (30 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes for immunoblotting, which were then blocked with 5% skim milk and incubated with primary antibodies overnight at 4 °C. The membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature and then developed using a chemiluminescent detection system (Pierce ECL Substrate Western Blot Detection System; Thermo Scientific, Rockford, MA, USA) and autoradiographic film (Kodak XAR flm). β-actin was used as a loading control. The primary antibodies were as follows: anti-PARP / activated PARP (1:1000, 13371-1-AP, Proteintech, USA), Bax (1:5000, 50599-2-Ig, Proteintech, USA), Bcl-2 (1:5000, 12789-1-AP, Proteintech, USA), anti-phospho-p44 / 42 MAPK (Erk1 / 2) (1:1000, 4370, Cell Signaling Technology, USA), anti-p44 / 42 MAPK (Erk1 / 2) (1:1000, 4695, Cell Signaling Technology, USA), RRM2 (1:1000, A5504, Bimake, USA), E2F3 (1:1000, DF12390, Affinity Biosciences, USA) and β-actin (1:3000, 20536-1-AP, Proteintech, USA). Secondary antibodies were as follows: HRP-conjugated Affinipure Goat Anti-Rabbit IgG (H+L) (1:5000, SA00001-2, Proteintech, USA). The detection was repeated three times.

[0055] The results are as follows Figure 1 As shown in I, revavafenib reduced the levels of G1 phase regulatory proteins CDK4 and cyclin D1 in Sk-Mel-2 and Sk-Mel-28 cell lines.

[0056] (6) Transwell assay and wound healing assay

[0057] To investigate the effects of rivafenib on the invasion and migration of melanoma cells, the researchers performed Transwell assays and wound healing assays.

[0058] The wound healing assay was performed as follows: 5 × 10 5 SK-MEL-2 / 28 cells were seeded into 6-well plates for adherence culture and scratched with a 200 μl sterile pipette tip. The scratched area was captured at 0, 24, and 48 h, and the migration rate was measured using Image J.

[0059] Transwell assay was performed as follows: SK-MEL-2 and SK-MEL-28 cells were treated with 0, 2.5, 5, and 10 μM revaccib for 48 h and then plated at the same density (5 × 10 cells per well). 4 Cells, 200 μl) were resuspended and seeded in the upper chamber (24-well migration chamber, 8.0 μm pore membrane, Corning, USA) in serum-free medium. The upper chamber was pre-coated with or without Matrigel (Sigma). Then, 800 μl of culture medium containing 10% FBS was injected into the lower chamber. After 24 hours of culture, the non-invasive cells on the upper side of the upper chamber were wiped with a cotton swab. The lower side of the upper chamber was fixed with 4% paraformaldehyde and stained with crystal violet. Five fields of view were randomly selected to count the invading or migrating cells. The test was repeated three times independently.

[0060] Transwell assays pre-coated with extracellular matrix gel showed that rivafenib reduced the number of invading cells ( Figure 3 A). In addition, the transwell assay with extracellular matrix gel without cells further demonstrated that rivarofenib significantly reduced the number of migrating cells compared with the control group ( Figure 3 B). In addition, our results showed that rivafenib inhibited wound healing of melanoma cells in a concentration-dependent manner ( Figure 3 CD). These results suggest that rivafenib has the ability to block the invasion and migration of melanoma cells.

[0061] (7) Immunofluorescence staining

[0062] SK-MEL-2 and SK-MEL-28 cells (5×10 4Cells were seeded into 6-well plates. After 12 hours, cells were treated with 0, 2.5, 5, and 10 μM concentrations of rivafenib for 48 hours. Cells were then fixed with 4% paraformaldehyde, permeabilized with tritonX-100, nonspecific antigens were blocked with 5% bovine serum, and incubated overnight at 4°C with anti-activated PARP (1:100, 380374, Zenbio, China), anti-Bcl-2 (1:100, 12789-1-AP, Proteintech, USA), and anti-Bax (1:100, PAB46088, Bioswamp, China). Cells were incubated with FITC-conjugated secondary antibodies (1:100, GB22403, Servicebio, China) for 1 hour, and then the nuclei were stained with DAPI (G1012, Servicebio, China) for 2 minutes. Finally, apoptotic cells were observed with a fluorescence microscope, and the number of cells was measured with Image J.

[0063] After treating melanoma cells with 0, 2.5, 5, and 10 μM concentrations of revavafenib for 48 hours, we observed an increase in floating round apoptotic cells, suggesting that revavafenib may induce apoptosis in melanoma cells. To confirm this, we detected the expression of apoptosis-related proteins such as activated PARP, Bax, and Bcl-2. Western blot analysis and immunofluorescence staining showed that in SK-Mel-2 and SK-Mel-28 cell lines treated with revavafenib, the expression of Bax and activated PARP increased, while the expression of Bcl-2 decreased ( Figure 4 AB), inducing apoptosis of melanoma cells. In addition, FCM also performed AnnexinV / 7-AAD double staining to detect apoptotic cells after revavafenib treatment. FCM results showed that the frequency of apoptotic cells in the revavafenib treatment group was much higher than that in the control group ( Figure 4 C). These results suggest that rivafenib can induce apoptosis in melanoma cells.

[0064] (8) Quantitative real-time PCR (qRT-PCR)

[0065] Total RNA was extracted using TRIzol reagent (R401-01, Novozyme, China), and then 1 μg RNA was reverse transcribed into cDNA using PrimeScriptRT reagent kit (R323-01, Novozyme, China) according to the manufacturer's instructions. QRT-PCR was performed on a Step Oneplus real-time PCR system using 2xSYBR Green qPCR Master Mix (B21202, Bimake, USA). The running conditions were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds, and 72°C for 30 seconds, followed by a melting curve at 95°C for 15 seconds, 60°C for 1 minute, and 95°C for 15 seconds. According to 2 -△△t Methods The relative expression of each gene was calculated. β-actin was used as an internal control for normalization. The primer sequences are shown in Table S1. The assay was repeated three times.

[0066] Table S1 Primer sequences

[0067]

[0068] To explore and identify the exact mechanism of changes in mRNA levels between the revavafenib-treated group and the control group treated with DMSO at a concentration of 1 / 1000 μM, the researchers used RNA-seq to analyze the transcriptomes of three revavafenib-treated and three control group samples. To confirm the reliability of the revavafenib-treated and control group samples, principal component analysis (PCA) was performed on the six samples. The principal component analysis showed that there were significant differences between the revavafenib-treated and control samples ( Figure 5 AB), indicating that differential mRNA expression contains key information to distinguish the two conditions. Next, the differentially expressed genes (DEGs) between rivafenib-treated and control samples were determined. The adjusted p value < 0.05 and |log 2 FC|≥1 was the critical value. 1502 upregulated DEGs and 780 downregulated DEGs were found in the rivafenib-treated samples ( Figure 5 C). The expression of some DEGs may increase or decrease after revaccine treatment. Here, we randomly selected the downregulated DEGs for further analysis. The downregulated DEGs were used for enrichment analysis, including gene ontology (GO) and Kyoto Encyclopedia of Genomes (KEGG). Enrichment analysis showed that the downregulated genes in revaccine-treated samples were enriched in multiple pathways, such as angiogenesis, response to bacteria, receptor regulatory activity, receptor ligand activity, proximal promoter sequence-specific DNA binding, transcriptional activator activity, and MAPK signaling pathway ( Figure 5DE). These results suggest that revavafenib may inhibit the pathogenesis of melanoma by preventing transcriptome changes in related genes. To identify key regulatory factors in the pathogenesis of melanoma, we performed a comprehensive analysis of a public melanoma dataset (GSE7553) and found 389 upregulated genes and 1467 downregulated genes in melanoma specimens. Through the comprehensive analysis of RNA-seq_down genes and GSE7553_up genes, we finally found 25 overlapping DEGs (ODEGs), which may be involved in the inhibitory effect of revavafenib on melanoma development ( Figure 5 F, Table S2). 2 Under the premise of FC|≥1, genes that were too much or too little studied in melanoma were eliminated. In the end, only four genes were obtained (GINS2, RRM2, FEN1, and UHRF1). In addition, the mRNA levels of these genes were tested when melanoma cells were treated with different concentrations of rivafenib. The results showed that only the mRNA changes of RRM2 were reasonable ( Figure 6 ). At the same time, studies have shown that targeting RRM2 is considered a feasible method for treating melanoma. This suggests that RRM2 may play an important role in the etiology of melanoma. Therefore, RRM2 was selected as the downstream target of revavafenib. Here, we want to know whether RRM2 is involved in the inhibition of the malignancy of melanoma by revavafenib. The results showed that different doses of revavafenib reduced the expression of RRM2 protein in melanoma cells ( Figure 5 G). In addition, we performed molecular docking to determine the interaction between RRM2 protein (Protein Data Bank (PDB) code: 2uw2) and rivafenib: Figure 5 As shown in Figure 3, the docking results show that the binding energy between RRM2 and revavafenib is -6.25 kcal / mol. Revavafenib interacts with residues ASP-271 and SER-263 by forming hydrogen bonds. All these results indicate that RRM2 is a participant in the inhibition of melanoma progression by revavafenib and is also a target of revavafenib in melanoma.

[0069] Table S2 25 ODEGs of RNA-seq_down genes and GSE7553_up genes

[0070]

[0071]

[0072] (9) HE staining

[0073] To investigate the role of RRM2 in the pathogenesis of melanoma, we eliminated the expression of RRM2 in Sk-Mel-2 and Sk-Mel-28 cell lines using a siRNA-based approach. Vital organs of tumor xenograft models were fixed with 4% paraformaldehyde and embedded in paraffin. Five-micron sections were obtained and stained with hematoxylin and eosin (H&E). Histopathological changes were observed under a microscope. Three independent assays were performed in duplicate.

[0074] Western blot analysis confirmed the removal efficiency of RRM2 ( Figure 7 A). We selected siRRM2-2# and 3# with higher silencing efficiency for additional functional studies. CCK8 and EDU staining showed that silencing RRM2 could significantly inhibit the proliferation of Sk-Mel-2 / 28 cells ( Figure 7 BE). In addition, loss of RRM2 can reduce the number of invasive cells and delay wound closure in melanoma cells ( Figure 7 FI). Our results showed that, like revavafenib, RRM2 knockdown also significantly reduced the proliferation, invasion, and migration of melanoma cells.

[0075] (10) Cell transfection

[0076] To investigate whether and how RRM2 is involved in revavafenib-induced inhibition of melanoma cell proliferation, RRM2 overexpression plasmid ( Figure 8 ) were transfected into Sk-Mel-2 / 28 cells, and then the cells were treated with rivarofenib for 48 h. siRNA targeting RRM2 and E2F3 and RRM2 overexpression plasmid were designed and synthesized by Qingke Bio (China) Co., Ltd. siRNAs and plasmids were transfected into SK-Mel-2 and SK-Mel-28 cells using EndoFectinTM Max transfection reagent (EF013, GeneCopoeia) according to the manufacturer's operating procedures. After 72 h of transfection, the silencing efficiency was detected by Western blotting. The target sequences are shown in Table S1. Three independent tests were repeated.

[0077] CCK8 cytotoxicity assay showed that RRM2 overexpression could partially inhibit revavafenib-induced melanoma cell cytotoxicity ( Fig. 9 A). In addition, FCM analysis showed that RRM2 overexpression seemed to partially inhibit revavafenib-induced apoptosis in melanoma cells ( Fig. 9 BC). In addition, we also observed that overexpression of RRM2 partially reversed the inhibition of melanoma cell invasion and migration induced by rivafenib ( Fig. 9DE). These data suggest that RRM2, as a target of revavafenib, is involved in the inhibitory effect of revavafenib on melanoma growth. Revavafenib inhibits the growth, invasion, and migration of melanoma cells by reducing the expression of RRM2, but promotes their apoptosis.

[0078] (11) RNA sequencing (RNA-seq) and data analysis

[0079] 5×10 4 Sk-Mel-2 cells were treated with rivarofenib (DMSO or 10 μM), respectively. After 48 h of treatment, total RNA of Sk-Mel-2 cells was extracted. cDNA libraries were constructed for each RNA sample using the TruSeq Stranded mRNA Library Pretreatment Kit (Illumina, USA) according to the manufacturer's instructions. mRNA libraries were prepared from total RNA using the NEB Next Small RNA Library Preparation Tool. Before read mapping, adapter sequences and low-quality reads were removed from the raw reads to obtain clean reads. The clean reads were then aligned to the human genome (GRCh38, NCBI) using Hisat2. HTseq was used to calculate gene counts, and the RPKM method was used to determine relative gene expression. Differential expression analysis between two conditions / groups was performed using the DESeq2 R software package (1.16.1). The resulting P values ​​were adjusted using the Benjamin and Hochberg method to control the false discovery rate. DESeq2 will be less than 0.05 |log 2 Fold Change|≥1 was set as the cutoff criterion and defined as differentially expressed genes (DEGs) for further investigation in this study.

[0080] Our RNA-seq data showed that revavafenib-induced downregulated genes were enriched in the MAPK signaling pathway ( Figure 5 E). Therefore, we attempted to evaluate the expression of the classic MAPK signaling pathway, the ERK signaling pathway, when melanoma cells were exposed to an appropriate amount of revavafenib. Western blot analysis showed that revavafenib treatment reduced the expression of phosphorylated ERK (p-ERK) in melanoma cells ( Fig.10 A). Importantly, we found that E2F3, a downstream transcription factor of ERK signaling, was also one of the 25 ODEGs (Table S2). Therefore, we also evaluated the expression of E2F3. When the Sk-Mel-2 / 28 cell line was treated with ravalidomide in a dose-dependent manner, a similar decrease in E2F3 levels was observed ( Fig.10A). The above results indicate that ERK / E2F3 signaling is involved in the inhibitory effect of revavafenib on melanoma cells. To investigate how ERK / E2F3 signaling contributes to the inhibitory effect of revavafenib on melanoma cells, Sk-Mel-2 / 28 cells were treated with specific MEK inhibitors (PD0325901 and U0126) or siRNA-E2F3 to limit ERK signaling or E2F3 expression. Western blot analysis showed that when ERK signaling was blocked, the levels of p-ERK, E2F3, and RRM2 were reduced ( Fig.10 B). In addition, we noticed that when E2F3 expression was reduced, RRM2 expression was also reduced, suggesting that RRM2 is a downstream molecule of E2F3 ( Fig.10 C). Our data suggest that revavafenib inhibits melanoma progression via the ERK / E2F3 / RRM2 axis.

[0081] (12) Tumor xenograft model

[0082] BALB / c nude mice, female, 4-6 weeks old, were housed in the SPF environment of Tongji Medical College, Huazhong University of Science and Technology. SK-Mel-2 / 28 cells (10 7 cells, 100ul) were injected subcutaneously into the right waist of the mice. About 10 days later, the mice were randomly divided into three groups and treated with drugs or 10mg / kg revavafenib by gavage every two days. The tumor size and volume were measured every three days. The tumor volume was calculated as follows: Volume (mm 3 )=(0.523)×length (mm)×width (mm)×height (mm). When the xenograft tumors in the control group reached about 1 cm 3 When the number of cells reached 400, the mice were killed, and the xenograft tumor tissues and important organs were removed, photographed, weighed, and preserved for further study.

[0083] To demonstrate that revavafenib reduces tumorigenesis in vivo, we established tumor xenografts using SK-Mel-28 and RRM2-overexpressing SK-Mel-28 (which we call SK-Mel-28-RRM2) and performed treatment experiments. Nude mice were first injected subcutaneously with melanoma cells. After tumor formation, the animals were injected intragastrically with solvent and 10 mg / kg revavafenib every two days. The in vivo experimental layout is as follows Fig.11 A. The results showed that revavafenib inhibited the growth of xenograft tumors ( Fig.12 AC). To enhance the credibility of the in vivo experiments, we also used another melanoma cell line, SK-Mel-2, to establish a tumor xenograft model and obtained the same results ( Fig.11BD). In addition, Western blot analysis of xenograft tumors showed that rivafenib treatment suppressed the levels of p-ERK and RRM2, while RRM2 overexpression partially alleviated the suppression of p-ERK and RRM2 expression ( Fig.12 D), which further confirmed the results of in vitro experiments.

[0084] In order to detect the toxicity of revavafenib to the host, the heart, liver, spleen, lungs and kidneys of the mice were removed and weighed for further histological examination. There was no significant change in the weight of these important organs in the control group and the revavafenib treatment group treated with DMSO at a concentration of 1 / 1000 μM ( Fig.12 E). In addition, no obvious histological changes were observed in these important organs in the control group and the rivafenib treatment group ( Fig.11 E), which confirmed that rivafenib had no significant toxicity to the host at an effective dose. These data demonstrate that rivafenib has the potential to reduce tumorigenesis in vivo.

[0085] Example 4 Molecular Docking

[0086] The SDF format three-dimensional structure file of rivafenib was obtained from the PubChem database and then converted to the PDB format using Open Babel. The three-dimensional crystal structure of RRM2 was also obtained from the PDB database and then processed by PyMol 2.4.0 to remove ions and water molecules to obtain the PDB file. Therefore, rivafenib and RRM2 were converted to PDBQT format to find the active pocket. Finally, molecular docking was performed using AutoDockTools 1.5.7, and the results were visualized by Pymol. The binding energy of the relevant active molecules was ≦-5.0 kJ / mol, indicating that these molecules were well docked with the target and could bind spontaneously.

[0087] Example 5 Quantification and statistical analysis

[0088] Statistical analysis was performed using GraphPad Prism software. Data are presented as mean + / - SEM. Unpaired t-test was used for statistical analysis between two groups. One-way analysis of variance (ANOVA) was used for statistical analysis between multiple groups. P values ​​less than 0.05 were considered to be significantly different.

[0089] The above are only preferred embodiments of the present invention, and do not limit the patent scope of the present invention. For those skilled in the art, the present invention may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the patent protection scope of the present invention.

Claims

1. Application of rivafenib in the treatment of melanoma.

2. The use according to claim 1, characterized in that The revavafenib can limit the growth, invasion and metastasis of melanoma cells.

3. The use according to claim 1, characterized in that The revavafenib upregulates apoptosis-inducing markers, including activated PARP and Bax.

4. The use according to claim 1, characterized in that The rivafenib exerts an anti-melanoma progression effect by reducing RRM2 expression.

5. The use according to claim 4, characterized in that The RRM2 is the target of rivafenib in melanoma.

6. The use according to claim 1, characterized in that The revavafenib inhibits the pathogenesis of melanoma via the ERK / E2F3 / RRM2 axis.

7. The use according to any one of claims 1 to 6, characterized in that The drug further comprises pharmaceutically acceptable excipients.

8. The use according to any one of claims 1 to 6, characterized in that The medicine is an oral preparation or an injection preparation.

Citation Information

Patent Citations

  • Application of regorafenib in preparation of drug for treating brain glioma

    CN110772514A